Vyriad, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Rochester MN United States (2016)

Organization Overview

First Clinical Trial
2016
NCT02962167
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Vyriad, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Squamous Cell (Phase 1)

Carcinoma, Transitional Cell (Phase 1)

Endometrial Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Measles (Phase 1)

Medulloblastoma (Phase 1)

Melanoma (Phase 2)

Neoplasms (Phase 1)

Rhabdoid Tumor (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 7